Michael Barbella, Managing Editor07.13.23
DiagnaMed Holdings Corp. has launched Health GenAI, a new division focused on the development and commercialization of generative AI ready-made and customizable applications powered by GPT-4 to help improve patient outcomes, operational workflow, and efficiency. The company expects to launch at least three products from its Health GenAI division this year.
DiagnaMed is organized to focus on its two divisions, CERVAI, a generative AI brain health platform, and Health GenAI. According to Market.us, generative AI in the healthcare market is set to reach approximately $17 billion by 2032, driven by the adoption of automation by healthcare operators in drug discovery and development, medical imaging and diagnostics, personalized medical interventions, and hospitals and clinical decision support systems.
“We are passionate about developing new generative AI-powered SaaS products to serve the needs of the healthcare sector. With the launch of our new division, Health GenAI, we are focusing on commercializing at least three generative AI solutions for the healthcare market and on complementing CERVAI, our generative AI brain health platform,” DiagnaMed Chairman Fabio Chianelli said.
As part of its Health GenAI division, the company unveiled its first commercial product, FormGPT.io, a generative AI data collection and analysis solution for the healthcare market, which was born from the development experience and features of CERVAI. FormGPT.io allows licensed medical professionals, hospitals, and life sciences entities to create customized forms and surveys with the support of ChatGPT and collect relevant patient data, obtain pre-and-post-visit and treatment feedback, monitor patient progress, and analyze results for decision-making. FormGPT.io empowers licensed professionals and clinical researchers to easily and quickly develop forms and surveys that complement their workflow and specific patient and research objectives. In addition, FormGPT.io aims to improve user services, workflow, patient outcomes and engagement.
DiagnaMed Holdings Corp., a generative AI healthcare solutions company, is focused on developing and commercializing CERVAI, a proprietary brain health AI platform, and Health GenAI, a suite of generative AI SaaS products for the healthcare market.
DiagnaMed is organized to focus on its two divisions, CERVAI, a generative AI brain health platform, and Health GenAI. According to Market.us, generative AI in the healthcare market is set to reach approximately $17 billion by 2032, driven by the adoption of automation by healthcare operators in drug discovery and development, medical imaging and diagnostics, personalized medical interventions, and hospitals and clinical decision support systems.
“We are passionate about developing new generative AI-powered SaaS products to serve the needs of the healthcare sector. With the launch of our new division, Health GenAI, we are focusing on commercializing at least three generative AI solutions for the healthcare market and on complementing CERVAI, our generative AI brain health platform,” DiagnaMed Chairman Fabio Chianelli said.
As part of its Health GenAI division, the company unveiled its first commercial product, FormGPT.io, a generative AI data collection and analysis solution for the healthcare market, which was born from the development experience and features of CERVAI. FormGPT.io allows licensed medical professionals, hospitals, and life sciences entities to create customized forms and surveys with the support of ChatGPT and collect relevant patient data, obtain pre-and-post-visit and treatment feedback, monitor patient progress, and analyze results for decision-making. FormGPT.io empowers licensed professionals and clinical researchers to easily and quickly develop forms and surveys that complement their workflow and specific patient and research objectives. In addition, FormGPT.io aims to improve user services, workflow, patient outcomes and engagement.
DiagnaMed Holdings Corp., a generative AI healthcare solutions company, is focused on developing and commercializing CERVAI, a proprietary brain health AI platform, and Health GenAI, a suite of generative AI SaaS products for the healthcare market.